News
Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopa ...
In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...
SAN FRANCISCO — Reduced doses in antifibrotic therapy for patients with idiopathic pulmonary fibrosis did not significantly impact outcomes, according to an abstract presented at the American ...
In patients not taking background antifibrotic therapy, the FVC decline was –79.2 mL for the 18-mg nerandomilast group compared with –148.7 mL for placebo.
Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis.
The FDA has granted Breakthrough Therapy designation to BMS-986278, an investigational LPA1 antagonist, for progressive pulmonary fibrosis.
Jean-Francois J. Dufour, MD, and Marshall M. Kaplan, MD, review the evidence and discuss how interferon may change the natural history of chronic hepatitis C independent of its antiviral effect.
New analyses from Akero highlight EFX's antifibrotic activity in pre-cirrhotic MASH patients, using AI-based digital pathology.
Utility of Antifibrotic Therapy Two antifibrotic therapies were approved in the US for the treatment of IPF in 2014: nintedanib and pirfenidone.
HONOLULU -- A reduced-dose regimen of the antifibrotic medication nintedanib (Ofev) held up in real-world clinical practice, an observational study found.
Gastroenterology > General Hepatology Novel Antifibrotic Improved Fibrosis in Chronic Hepatitis B — Phase II trial from China suggests benefit of add-on therapy by Zaina Hamza, Staff Writer ...
SOUTH SAN FRANCISCO, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced positive 24-week data from the 320 mg cohort of INTEGRIS-PSC, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results